Loading stock data…
Allarity Therapeutics (ALLR)
$1.29-0.01 (-0.77%)
Market OpenUpdated 1:57 PM EDT
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Allarity Therapeutics, Inc. in the Healthcare sector is trading at $1.29 with a market capitalization of $23M. Wall Street consensus targets $10.25 (1 analysts), implying a +694.6% move over the next 12 months. The stock is currently 45% below its 52-week high of $2.35, remaining 0.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +694.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25,000↓ | $320,000 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.69M↑ | -$2.92M↓ | -$2.52M↑ | -$4.13M↓ | -$3.04M |
| Net Income | -$2.75M↑ | -$3.37M↓ | -$2.81M↓ | -$2.32M↑ | -$2.73M |
Peer Comparison
JNJUNHPFE
Fundamentals
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the persona...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-162.56%
Volume
Today's trading volume
33,784
Recent News
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited - Sponsored ADR (ATHE) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
Allarity closes $20M financing for stenoparib advancement
Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: a promissory note in the original principal amount of $10,930,000 and a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company. The financing is expected to extend
Allarity CEO says 2026 represents an ‘inflection point’
Allarity (ALLR) Therapeutics issued a letter to shareholders from the Company’s CEO, which read, in part, “As we close out 2025, I write to you with both optimism and gratitude. Your continued support has helped steer Allarity Therapeutics through a period of meaningful transformation and disciplined execution. This December marks two years since I assumed the role of CEO. Since that time, our efforts have been anchored by a clear and focused strategy centered on advancing stenoparib, our novel